# US 2012/0251531 A1 · ANTIBODY Fc VARIANTS

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251531 A1
- Document ID: US20120251531A1
- Status: Published application
- Kind: A1
- Application number: 13/431,489
- Filed: 2012-03-27
- Published: 2012-10-04
- Earliest claimed: 2011-03-29
- Assignees: Genentech, Inc.
- Inventors: Monika Baehner; Stefan Jenewein; Manfred Kubbies; Ekkehard Moessner; Tilman Schlothauer
- Web page: https://patentgrep.com/patent/US20120251531A1

## CPC

- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- Y10S 435/81: Packaged device or kit
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The invention relates to engineered polypeptides comprising Fc variants and their uses. More specifically, Fc variants are described exhibiting reduced effector function. These variants cause a benefit for a patient suffering from a disease which could be treated with an antibody for which it is desirable to reduce the effector function elicited by antibodies.

## Claims

### Claim 1

A polypeptide comprising an Fc variant of a wild-type human IgG Fc region, said Fc variant comprising an amino acid substitution at position Pro329 and at least one further amino acid substitution, wherein the residues are numbered according to the EU index of Kabat, and wherein said polypeptide exhibits a reduced affinity to one or more of human FcγRIIIA, FcγRIIA, and FcγRI compared to the polypeptide comprising the wildtype IgG Fc region, and wherein the antibody-dependent cell-mediated cytotoxicity (ADCC) induced by said polypeptide is reduced to at least 20% of the ADCC induced by the polypeptide comprising a wild-type human IgG Fc region.

### Claim 2 (depends on 1)

The polypeptide according to claim 1, wherein Pro329 of the wild-type human Fc region is substituted with glycine or arginine or an amino acid residue large enough to destroy the proline sandwich within the Fc region.

### Claim 3 (depends on 1)

The polypeptide according to claim 1, wherein said at least one further amino acid substitution is selected from S228P, E233P, L234A, L235A, L235E, N297A, N297D, and P331S.

### Claim 4 (depends on 3)

The polypeptide according to claim 3, wherein said at least one further amino acid substitution is L234A and L235A of the human IgG1 Fc region or S228P and L235E of the human IgG4 Fc region.

### Claim 5 (depends on 1)

The polypeptide according to claim 1, wherein the affinity to at least one further human receptor reduced compared to the polypeptide comprising a wild-type human IgG Fc region wherein the further human receptor is selected from FcγI, FcγIIA, and C1q.

### Claim 6 (depends on 1)

The polypeptide according to claim 1, wherein the polypeptide comprises a human IgG1 or IgG4 Fc region.

### Claim 7 (depends on 1)

The polypeptide according to claim 1, wherein the polypeptide is an antibody or an Fc fusion protein.

### Claim 8 (depends on 1)

The polypeptide according to claim 1, wherein thrombocyte aggregation induced by the polypeptide is reduced compared to the thrombocyte aggregation induced by a polypeptide comprising a wild-type human IgG Fc region.

### Claim 9 (depends on 1)

The polypeptide according to claim 1, wherein CDC induced by the polypeptide is strongly reduced compared to the CDC induced by a polypeptide comprising a wild-type human IgG Fc region.

### Claim 10

(canceled)

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The polypeptide according to any one of claims 1-9, wherein the polypeptide is an anti-CD9 antibody comprising a heavy chain variable region comprising SEQ ID NO:9 and a variable light chain region comprising SEQ ID NO:8.

### Claim 12 (depends on 20)

A method of treating a disease comprising administering the polypeptide according to claim 20, wherein it is favorable for treating the disease that an effector function of the polypeptide is strongly reduced compared to the effector function induced by the polypeptide comprising a wild-type human IgG Fc region.

### Claim 13

(canceled)

### Claim 14 (depends on 20)

A method of treating an individual having a disease, wherein it is favorable that the effector function of the polypeptide comprising an Fc variant of a wild-type human IgG Fc region is strongly reduced compared to the effector function induced by the polypeptide comprising a wildtype human Fc polypeptide, comprising administering to an individual an effective amount of the polypeptide according to claim 20.

### Claim 15

A method for down-modulating ADCC comprising a polypeptide comprising an Fc variant of a wild-type human IgG Fc region, said polypeptide having Pro329 of the human IgG Fc region substituted with glycine, wherein the residues are numbered according to the EU index of Kabat, wherein said polypeptide exhibits a reduced affinity to the human FcγRIIIA and FcγRIIA, wherein ADCC is down-modulated to at least 20% of the ADCC induced by the polypeptide comprising the wildtype human IgG Fc region.

### Claim 16 (depends on 15, 22)

The method according to any one of claims 15, 22, or 23 wherein the Fc variant comprises at least two further amino acid substitution at L234A and L235A of the human IgG1 Fc region or S228P and L235E of the human IgG4 Fc region.

### Claim 17 (depends on 16)

The method of claim 16, wherein thrombocyte aggregation induced by the polypeptide is reduced compared to the thrombocyte aggregation induced by the polypeptide comprising a wildtype human Fc region, wherein the polypeptide is a platelet activating antibody.

### Claim 18

A method of treating an individual having a disease with a polypeptide, said polypeptide having Pro329 of the human IgG Fc region substituted with Gly, wherein the residues are numbered according to the EU index of Kabat, wherein said polypeptide is characterized by a strongly reduced binding to FcγRIIIA and FcγRIIA compared to the polypeptide comprising a wildtype human IgG Fc region, comprising administering to the individual an effective amount of said polypeptide.

### Claim 19 (depends on 18)

The method according to claim 18, wherein said polypeptide comprises at least two further amino acid substitution at L234A and L235A of the human IgG1 Fc region or S228P and L235E of the human IgG4 Fc region.

### Claim 20 (depends on 11)

A pharmaceutical formulation comprising the polypeptide according to claim 11.

### Claim 21 (depends on 11)

An article of manufacture comprising the polypeptide according to claim 11.

### Claim 22 (depends on 15)

The method of claim 15 further comprising down-modulating antibody-dependent cellular phagocytosis (ADCP).

### Claim 23

A method for down-modulating ADCP comprising a polypeptide comprising an Fc variant of a wild-type human IgG Fc region, said polypeptide having Pro329 of the human IgG Fc region substituted with glycine, wherein the residues are numbered according to the EU index of Kabat, wherein said polypeptide exhibits a reduced affinity to the human FcγRIIIA and FcγRIIA.
